MedTrace Logo

Use of Nebido® to Assess Tolerability and Treatment Outcomes in Daily Clinical Practice

NCT00410306 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1493

Last updated 2010-09-24

No results posted yet for this study

Summary

This is an observational study with a drug called Nebido, a new testosterone replacement therapy, which is available for the treatment of male hypogonadism. The benefit and safety of Nebido have already been thoroughly evaluated through well controlled clinical trials. The main purpose of this observational study is to confirm the established safety profile of Nebido in daily clinical practice.

Conditions

  • Male
  • Hypogonadism

Interventions

DRUG

Testosterone Undecanoate (Nebido, BAY86-5037)

Patients from routine practice

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-10-31
Primary Completion
2010-07-31
Completion
2010-07-31

Countries

  • Australia
  • Austria
  • Bulgaria
  • Colombia
  • Czechia
  • Estonia
  • Germany
  • Hong Kong
  • Indonesia
  • Italy
  • Jordan
  • Kazakhstan
  • Latvia
  • Lebanon
  • Lithuania
  • Malaysia
  • Malta
  • Mexico
  • Moldova
  • North Macedonia
  • Philippines
  • Romania
  • Russia
  • Saudi Arabia
  • Singapore
  • Slovenia
  • South Korea
  • Spain
  • Taiwan
  • Thailand
  • Turkey (Türkiye)
  • Ukraine
  • United Kingdom

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00410306 on ClinicalTrials.gov